{"id":128643,"title":"Blank Bio - Biological AI Models to Predict Patient Outcomes","tagline":"We predict patient survival and treatment response to increase clinical trial success ","body":"**TL;DR:**\n\nToday, we are excited to introduce [Ladon](https://www.blank.bio/introducing-ladon), a state-of-the-art RNA foundation model that predicts disease trajectory and treatment response in patients. There is immense complexity in the individual biology of every patient. Two patients can have the same diagnosis and receive the same treatment, yet have very different outcomes: one responds well and lives for years, while the other’s disease continues to progress. Understanding and resolving this heterogeneity to predict outcomes is how we unlock clinical trial abundance and ultimately accelerate our delivery of medicines for patients. Ladon is our first step towards this future: one where we can learn more from every patient enrolled so that we can run smaller, faster trials with higher success rates. We built it to give drug developers quantitative support on billion-dollar clinical trial decisions.\n\n**Ask:** Do you know someone in clinical development or translational medicine at a pharma or biotech? We’d love an introduction. Please email us at [founders@blank.bio](mailto:founders@blank.bio)\n\n![uploaded image](/media/?type=post&id=128643&key=user_uploads/1842799/7216db80-e659-487b-8cb8-d478539fbff6)\n\n— \n\n### The Problem\n\nDrugs are getting easier to design, but the bottleneck is still the clinic: 95% of cancer drugs that enter clinical trials never get approved. With more therapies to test than ever before, clinical trial decisions become harder and harder. This is in large part due to patient heterogeneity. Two patients can have the same diagnosis and receive the same treatment, yet have very different outcomes: one responds well and lives for years, while the other’s disease continues to progress. Fundamentally, the challenge with making clinical trial decisions is that we don’t have good enough tools to reliably predict therapeutic response and patient prognosis.\n\n### Our solution\n\n* Ladon is a 3B parameter model trained on millions of RNA-seq samples that span decades of data across labs, sequencing machines, cell lines, animal models, humans, and more.\n* We are state-of-the-art, beating gene expression baselines, established biomarkers, and existing RNA foundation models at predicting patient prognosis and therapeutic response in various settings spanning 120+ oncology tasks, including external validation on 8 retrospectively analyzed clinical trials.\n* More importantly, we demonstrate that Ladon-derived predictions are also robust and generalize across tissue and clinical trial cohorts. In the technical report, you’ll see that every evaluation is measured in an out-of-distribution setting like a held-out clinical trial, another cohort, or another measurement platform.\n* We’ve built it with interpretability in mind. We also show that Ladon is best-in-class at inferring cell composition of bulk RNA-seq samples to make insights actionable.\n\n### For pharma and diagnostic companies\n\nAll Ladon needs is RNA-seq from tumor samples. If you have banked samples, **we will pay for the RNA-sequencing costs!** Here are some potential applications:\n\n* **Help with go / no-go decision making:** will a Phase 2 response turn into a survival benefit in Phase 3?\n* **Contextualize single-arm trial results**: build synthetic control arms to see how patients would’ve done on standard of care\n* **End trials earlier:** adjusting for prognostic signal at baseline can increase trial efficiency and end trials months earlier. Get to market faster!\n* **Develop novel signatures:** find prognostic and predictive signal that actually hold up in the real world. We can also show that your biomarker is truly predictive by adjusting for prognostic baselines\n\n### Our ask\n\n* Please [reach out](https://www.blank.bio/contact) to us if you’d like to get access to the model\n* You can read our [blog](https://www.blank.bio/introducing-ladon) and [technical report](https://www.blank.bio/ladon-technical-report) for more technical details\n* If you know any clinical development or translational leaders across pharma or biotech, we’d love to get an intro\n\n<https://youtu.be/fIS6qyKh7L8>","slug":"XSt-blank-bio-biological-ai-models-to-predict-patient-outcomes","created_at":"2026-11-12T23:41:30.560Z","updated_at":"2026-11-18T08:10:12.242Z","total_vote_count":7,"url":"https://www.ycombinator.com/launches/XSt-blank-bio-biological-ai-models-to-predict-patient-outcomes","share_image_url":"https://www.ycombinator.com/media/?type=post&id=128643&key=user_uploads/1842799/1f2615b5-d84d-4929-9be1-3d7d754ba326","company":{"id":30613,"name":"Blank Bio","slug":"blank-bio","url":"http://blank.bio/","logo":"https://bookface-images.s3.amazonaws.com/small_logos/7849a6bd6406353cb8f9f09c914d22bd1f4c0650.png","batch":"Summer 2025","industry":"Healthcare","tags":[],"search_path":"https://bookface.ycombinator.com/company/30613"}}